ACTA1 and neoplasm: IHC further indicated the presence of CD45+ immune populations in the central regions of the tumor mass in PyMT tumors treated with mDKN01 (Fig. 5B), αSMA-Dkk1cKO animals (Fig. 5C) and from WT mice co-injected with tumor cells plus αSMA-Dkk1cKO CAFs (Fig. 5D).